Survival benefit of nivolumab was independent of PD-L1 expression levels in the SQ NSCLC trial (CheckMate-017) [3], contrast to the non-SQ NSCLC trail (CheckMate-057) in which OS benefit correlated with PD-L1 expression level [4]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.